AR124937A1 - Mutación estabilizante de trímeros de proteínas de la envoltura del vih - Google Patents
Mutación estabilizante de trímeros de proteínas de la envoltura del vihInfo
- Publication number
- AR124937A1 AR124937A1 ARP220100371A ARP220100371A AR124937A1 AR 124937 A1 AR124937 A1 AR 124937A1 AR P220100371 A ARP220100371 A AR P220100371A AR P220100371 A ARP220100371 A AR P220100371A AR 124937 A1 AR124937 A1 AR 124937A1
- Authority
- AR
- Argentina
- Prior art keywords
- hiv
- numbering
- recombinant
- protein
- env protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
- C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Reivindicación 1: Una proteína de la envoltura (Env) del virus de la inmunodeficiencia humana (VIH) recombinante que comprende uno de los aminoácidos triptofano (Trp), fenilalanina (Phe), metionina (Met) o leucina (Leu) en la posición 650, en donde la numeración de las posiciones es de acuerdo con la numeración en la gp160 de la forma aislada HXB2 del VIH-1. Reivindicación 11: Un complejo trimérico que comprende un oligómero no covalente de tres proteínas Env del VIH recombinantes idénticas de cualquiera de las reivindicaciones 1 - 10. Reivindicación 12: Una partícula, preferiblemente un liposoma o una nanopartícula, que expresa sobre su superficie una proteína Env del VIH recombinante de cualquiera de las reivindicaciones 1 a 10 o un complejo trimérico de la reivindicación 11. Reivindicación 13: Una molécula de ácido nucleico aislada que codifica una proteína Env del VIH recombinante de cualquiera de las reivindicaciones 1 a 10. Reivindicación 14: Un vector que comprende la molécula de ácido nucleico aislada de la reivindicación 13 ligada operativamente a un promotor. Reivindicación 16: Una célula huésped que comprende la molécula de ácido nucleico aislada de la reivindicación 13 o el vector de la reivindicación 14 ó 15. Reivindicación 17: Un método para producir una proteína Env del VIH recombinante, que comprende cultivar la célula huésped de la reivindicación 16 en condiciones adecuadas para la producción de la proteína Env del VIH recombinante. Reivindicación 18: Una composición que comprende la proteína Env del VIH recombinante de cualquiera de las reivindicaciones 1 a 10, el complejo trimérico de la reivindicación 11, la partícula de la reivindicación 12, la molécula de ácido nucleico aislada de la reivindicación 13 o el vector de la reivindicación 14 ó 15 y un vehículo farmacéuticamente aceptable. Reivindicación 19: Un método para mejorar la formación de trímeros de una proteína Env del VIH, comprendiendo el método sustituir un residuo de aminoácido en la posición 650 de una proteína Env del VIH parental por uno de Trp, Phe, Met o Leu, preferiblemente por Trp o Phe, en donde la numeración de las posiciones es de acuerdo con la numeración en la gp160 de la forma aislada HXB2 del VIH-1. Reivindicación 20: Una proteína de la envoltura (Env) del virus de la inmunodeficiencia humana (VIH) recombinante que comprende histidina (His) en la posición 108, en donde la numeración de la posición es de acuerdo con la numeración en la gp160 de la forma aislada HXB2 del VIH-1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21158800 | 2021-02-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR124937A1 true AR124937A1 (es) | 2023-05-24 |
Family
ID=74732664
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220100371A AR124937A1 (es) | 2021-02-23 | 2022-02-22 | Mutación estabilizante de trímeros de proteínas de la envoltura del vih |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220265813A1 (es) |
| EP (1) | EP4297778A1 (es) |
| JP (1) | JP2024509769A (es) |
| KR (1) | KR20230150269A (es) |
| CN (1) | CN116867517A (es) |
| AR (1) | AR124937A1 (es) |
| AU (1) | AU2022224967A1 (es) |
| CA (1) | CA3211197A1 (es) |
| MX (1) | MX2023009835A (es) |
| TW (1) | TW202302622A (es) |
| WO (1) | WO2022180007A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025245259A2 (en) * | 2024-05-21 | 2025-11-27 | Dana-Farber Cancer Institute, Inc. | Hiv-1 immunogen compositions and methods of using the same |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| WO2005034842A2 (en) * | 2003-05-19 | 2005-04-21 | Progenics Pharmaceuticals, Inc. | Peptides useful as hiv fusion inhibitors |
| WO2007104792A2 (en) | 2006-03-16 | 2007-09-20 | Crucell Holland B.V. | Recombinant adenoviruses based on serotype 26 and 48, and use thereof |
| BR122021004758B1 (pt) | 2008-11-18 | 2022-04-19 | Los Alamos National Security, Llc | Uso de um peptídeo viral otimizado, vacina e seu método de fabricação, vetor e kit |
| EP2451475A2 (en) | 2009-07-06 | 2012-05-16 | Novartis AG | Self replicating rna molecules and uses thereof |
| WO2011082087A2 (en) | 2010-01-04 | 2011-07-07 | Kj Biosciences, Llc | Dps fusion proteins for use in vaccines and diagnostics |
| GB201108879D0 (en) | 2011-05-25 | 2011-07-06 | Isis Innovation | Vector |
| WO2014078688A2 (en) | 2012-11-16 | 2014-05-22 | Beth Israel Deaconess Medical Center, Inc. | Recombinant adenoviruses and use thereof |
| US10248758B2 (en) | 2013-02-07 | 2019-04-02 | University Of Washington Through Its Center For Commercialization | Self-assembling protein nanostructures |
| EP3189067B1 (en) * | 2014-09-04 | 2021-05-19 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Recombinant hiv-1 envelope proteins and their use |
| US9630994B2 (en) | 2014-11-03 | 2017-04-25 | University Of Washington | Polypeptides for use in self-assembling protein nanostructures |
| EA038974B1 (ru) | 2015-12-15 | 2021-11-17 | Янссен Вэксинс Энд Превеншн Б.В. | Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения |
| MD3512543T2 (ro) | 2016-09-15 | 2020-11-30 | Janssen Vaccines & Prevention Bv | Mutații de stabilizare a trimerului proteinei de înveliș HIV |
| GB201708444D0 (en) | 2017-05-26 | 2017-07-12 | Univ Oxford Innovation Ltd | Compositions and methods for inducing an immune response |
| CN110891601A (zh) | 2017-07-19 | 2020-03-17 | 扬森疫苗与预防公司 | 三聚体稳定性hiv包膜蛋白突变 |
| KR102806640B1 (ko) | 2017-07-28 | 2025-05-12 | 얀센 백신스 앤드 프리벤션 비.브이. | 이종성 repRNA 면역접종을 위한 방법 및 조성물 |
| EP3697440A1 (en) * | 2017-10-16 | 2020-08-26 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Recombinant hiv-1 envelope proteins and their use |
| CN111295391B (zh) | 2017-10-31 | 2023-12-05 | 扬森疫苗与预防公司 | 腺病毒及其用途 |
| MX2020004488A (es) | 2017-10-31 | 2020-08-13 | Janssen Vaccines & Prevention Bv | Adenovirus y usos de estos. |
-
2022
- 2022-02-22 AR ARP220100371A patent/AR124937A1/es not_active Application Discontinuation
- 2022-02-22 KR KR1020237026810A patent/KR20230150269A/ko active Pending
- 2022-02-22 AU AU2022224967A patent/AU2022224967A1/en not_active Abandoned
- 2022-02-22 JP JP2023550223A patent/JP2024509769A/ja active Pending
- 2022-02-22 MX MX2023009835A patent/MX2023009835A/es unknown
- 2022-02-22 EP EP22707124.8A patent/EP4297778A1/en not_active Withdrawn
- 2022-02-22 CA CA3211197A patent/CA3211197A1/en active Pending
- 2022-02-22 WO PCT/EP2022/054336 patent/WO2022180007A1/en not_active Ceased
- 2022-02-22 US US17/651,973 patent/US20220265813A1/en not_active Abandoned
- 2022-02-22 TW TW111106284A patent/TW202302622A/zh unknown
- 2022-02-22 CN CN202280015572.XA patent/CN116867517A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230150269A (ko) | 2023-10-30 |
| CA3211197A1 (en) | 2022-09-01 |
| MX2023009835A (es) | 2023-09-04 |
| AU2022224967A9 (en) | 2024-05-16 |
| US20220265813A1 (en) | 2022-08-25 |
| TW202302622A (zh) | 2023-01-16 |
| EP4297778A1 (en) | 2024-01-03 |
| AU2022224967A1 (en) | 2023-07-27 |
| JP2024509769A (ja) | 2024-03-05 |
| CN116867517A (zh) | 2023-10-10 |
| WO2022180007A1 (en) | 2022-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR126987A2 (es) | Inmunoconjugados | |
| Tolosa et al. | The endogenous retroviral envelope protein syncytin-1 inhibits LPS/PHA-stimulated cytokine responses in human blood and is sorted into placental exosomes | |
| Blok et al. | Studies on the size, chemical composition, and partial sequence of the neuraminidase (NA) from type A influenza viruses show that the N-terminal region of the NA is not processed and serves to anchor the NA in the viral membrane | |
| AR124937A1 (es) | Mutación estabilizante de trímeros de proteínas de la envoltura del vih | |
| JP4926231B2 (ja) | 二量体化ペプチド | |
| US8450284B2 (en) | Coiled-coil lipopeptide helical bundles and synthetic virus-like particles | |
| US11666630B2 (en) | Polypeptides for managing viral infections | |
| BR112019019813A2 (pt) | moléculas quiméricas e usos das mesmas | |
| Suzuki et al. | The chemical structure of polymyxin E: the identities of polymyxin E1 with colistin A and of polymyxin E2 with colistin B | |
| AR056138A1 (es) | Procedimiento para la expresion recombinante de un polipeptido | |
| RU2014142785A (ru) | Оптимизированные с помощью вычислительных средств антигены с широким спектром реактивности для вирусов гриппа h5n1 и h1n1 | |
| AR088028A1 (es) | Proteinas h5, de h5n1 para un uso medicinal | |
| CL2022002208A1 (es) | Receptor de células t restringido por hla de la clase i contra ras con mutación | |
| KR102608122B1 (ko) | 도데카펩타이드의 개선된 제조 방법 | |
| TWI396741B (zh) | 非洲綠猴腎細胞培養之流感病毒及疫苗 | |
| CO2023000048A2 (es) | Conjugados de citoquina | |
| AR041764A1 (es) | Vacuna basada en polinucleotidos y proteinas derivados del vih | |
| MX2024008983A (es) | Polipeptidos quimericos | |
| AR041765A1 (es) | Vacuna a dna para la profilaxis y el tratamiento de infeccion por hiv | |
| KR102253190B1 (ko) | 지카 바이러스 변이주와 이를 포함한 지카 백신 조성물 | |
| JPWO2021070696A5 (es) | ||
| CN101874038A (zh) | 治疗性抗-hiv肽的合成方法 | |
| Menendez-Arias et al. | Purification of immature cores of mouse mammary tumor virus and immunolocalization of protein domains | |
| CN108699113A (zh) | 肽及其作为抗病毒剂的用途 | |
| Lee et al. | Structure-activity relationships of anti-HIV-1 peptides with disulfide linkage between D-and L-cysteine at positions i and i+ 3, respectively, derived from HIV-1 gp41 C-peptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |